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The obvious importance of metastatic spread in determining
clinical outcome in cancer patients has fuelled efforts to
increase understanding of the pathobiology of this process in
the hope that better understanding eventually can be trans-
lated into improved therapy. Considerable impetus was given
to the experimental analysis of the mechanisms underlying
tumour dissemination by the demonstration that populations
of metastatic and non-metastatic cells could pre-exist within
the same parental tumour (Fidler & Kripke, 1977). Selection
during the complex, sequential events of cancer spread might
ensure that the cellular composition of secondary tumours
differed from that ofprimary tumours (Poste & Fidler, 1980).
The opportunity was thus provided to define those charac-
teristics of importance in regulating metastatic spread by
comparing primary and secondary growths or by comparing
variant lines differing only in their malignant behaviour
(Hart et al., 1989). However, recent results with genetically
tagged cells have shown that, in certain tumour types, over-
growth of the primary tumour with metastatic cell popula-
tions can be a particularly rapid event (Kerbel et al., 1988).
Therefore, the identification of differences between local and
distant growths may not be feasible in all instances. Nonethe-
less recent efforts to identify and isolate specific genes con-
trolling metastatic behaviour often have utilised material
derived from primary and secondary growths. Alternatively
closely related variant lines with different metastatic potential
frequently have provided the starting material used in these
studies. These recent approaches to the direct identification
and isolation of genes determining the metastatic phenotype
form the subjects of this review.
Transfection studies
Conversion of non-metastatic tumour cells to the fully metas-
tatic phenotype has been achieved in a number of experi-
mental tumour systems by the relatively simple expedient of
transfecting the benign population with an activated onco-
gene, generally of the ras family (e.g. Kyprianou & Isaacs,
1990; Treiger & Isaacs, 1988). The process of metastasis has
been considered to be a complex phenomenon developing
late in tumour progression where accumulation of somatic
mutations, coupled with strong environmental selection pres-
sures, has led to the emergence of more aggressive clonal
subpopulations (Nowell, 1976). Regulation of the process has
been presumed to result from the activation/repression of a
number of specific genes (Nicolson, 1988). The conversion of
a benign to a malignant cell by a single gene may be explain-
able if the cells already express all other gene products
necessary for metastasis; the exogenous gene simply com-
pletes the requisite repertoire. More surprising is that
numerous groups have documented the fact that non-tumou-
rigenic fibroblast cell lines acquire metastatic activity follow-
ing transfection with either ras or protein kinase oncogenes
(Bradley et al., 1986; Egan et al., 1987a,b; Greig et al., 1985).
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Though both N1H3T3 and IOTI/2 lines used in these studies
are non-tumourigenic, a characteristic that is not always
steadfastly maintained (Greig et al., 1985), they have been
grown in tissue culture for extended periods of time. The
lines therefore may have accrued sufficient somatic mutations
to require only the addition of the benefits conferred by the
introduced gene to 'tip them over the edge' to full malig-
nancy; in certain instances this movement to malignancy may
be independent of the addition of any gene (Greig et al.,
1985). A somewhat similar picture is often apparent in
clinical situations. For example, while ras mutations fre-
quently occur at an early stage of development in certain
human cancers, it is the total accumulation, rather than the
order, of genetic alterations which appears to be the most
important determinant underlying tumour progression (Fea-
ron & Vogelstein, 1990). Less easy to understand in these
terms is the report that early passage embryo cells, presum-
ably relatively free of acquired mutations, can be rendered
fully metastatic by transfection with the ras oncogene alone
(Muschel et al., 1985). It could be that in this instance
introduction of the ras gene acted to increase genetic insta-
bility, thus accelerating the process of mutation acquisition,
or that it acted as a fundamental control gene, possibly to
regulate transcription of other genes involved in the metas-
tatic process (Liotta, 1988). Interestingly therefore ras trans-
fection has been accompanied by elevated expression of
various proteases; enzymes which have often been implicated
in the invasive process (Collier et al., 1988; Denhardt et al.,
1987; Garbisa et al., 1987).
Given that a single oncogene has resulted in acquisition
of the full malignant phenotype it is not surprising that
efforts have been made to isolate novel metastasis genes
by the transfection of high molecular weight DNA from
malignant cells into non-metastatic cells. As far as we are
aware no gene, other than an activated ras oncogene
(Thorgeirsson et al., 1985; Ananthaswamy et al., 1988, 1989),
has yet been isolated and identified by this approach,
although changes in metastatic behaviour have occurred as a
consequence of transfer ofgenomic DNA (Radler-Pohl et al.,
1988).
Differential screening ofcDNA libraries
A number of assumptions underlie the use of transfection
assays to detect genes conferring metastatic behaviour, not
the least of which is that recipient, non-metastatic cells
require a single, dominant gene for conversion to malig-
nancy. However in the last year or so considerable attention
has focused upon the possibility that genetic control of
metastasis may be exerted via the deactivation of metastasis
suppressor genes (Kerbel, 1989; Sobel, 1990) and such genes
would not be detected in the transfection assays. For exam-
ple Khokha and her colleagues (Khokha et al., 1989) have
shown that transfection of Swiss 3T3 cells with antisense
RNA to Tissue Inhibitor of Metalloproteinases (TIMP)
results in the gain offull metastatic capacity. Since an inverse
correlation exists between production of the 28.5 kDa TIMP
glycoprotein and the invasive capacity of transformed lines
(Hicks et al., 1984) is it feasible that the TIMP gene is acting
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as a suppressor of disseminative ability? Inactivation of the
TIMP gene product by mutation/loss, or by the artificial
introduction of antisense mRNA, could alter the normal
balance between protease and protease inhibitor in the cell
and thus lead to invasive and metastatic behaviour.
One way of detecting novel genes which may modulate
invasion and metastasis that does not suffer from the neces-
sity to score for a dominant trait is to utilise differential
screening of cDNA libraries. The objective here is to detect
cDNA clones corresponding to mRNAs which differ in abun-
dance between related cell populations. No assumption is
made as to the nature of the sought gene. The sensitivity of
the differential screening technique is limited to detection of
mRNA transcripts constituting >0.01% of the mRNA pop-
ulation; preliminary subtractive hybridisation raises this sen-
sitivity to allow detection of transcripts constituting
>0.001% of the mRNA (Hedrick et al., 1984). A number of
investigators have used this approach (see below) utilising
mRNA prepared from established cell lines of metastatic and
non-metastatic behaviour. Should primary and secondary
tumours actually be composed of different populations of
neoplastic cells-then the approach should be equally feasible
utilising fresh tumour tissues. Indeed Elvin et al. (1988) were
able to use such starting material to isolate cDNA clones
representing mRNAs differentially expressed during progres-
sion and metastasis of colorectal cancer. One possible com-
plication of this approach is the potentially different degree
of inflammatory cell infiltrate or tumour stroma between
tumours at different sites. Differential mRNA expression
simply might reflect cellular heterogeneity as a consequence
of tumour.location. Additionally cellular composition could
vary to a marked extent within the tumour mass; thus the
origin of the starting material could have a profound effect
on subsequent results. These problems are avoided by the
utilisation of pure cell lines.
To date the relatively small number of published studies
which have used this technique have identified a mixture of
novel and previously known genes. Thus Elvin et al. (1988)
isolated pLM59, following screening of a small library of
5,000 colonies, a cDNA coding for an 0.8 kb RNA transcript
which was more abundant in a liver metastasis than in either
normal or primary tumour material and which was expressed
preferentially in metastatic murine cell lines. The identified
sequence subsequently was shown to encode an acidic ribo-
somal phosphoprotein, P2 (Sharp et al., 1990) which plays a
role in protein translation (Rich & Steitz, 1987). Similarly
pGM21, a gene associated with high metastatic potential in
rat mammary adenocarcinomas, identified after a subtractive
hybridisation procedure, seems to be partially homologous to
human elongation factor I subunit a, which is involved in
protein synthesis (Phillips et al., 1990). In both these in-
stances metastatic capacity is associated with enhanced ex-
pression of the identified gene; an enhanced expression that
possibly relates more to the metabolic activity, and perhaps
the growth characteristics, of the lines being analysed than to
the obvious biochemical requirements of metastatic cells.
Rather more understandable is the up-regulation of transin
mRNA in squamous cell carcinomas as compared to non-
invasive papillomas (Matrisian et al., 1986). This is because
the metalloprotease encoded for by the transin gene, which
seems to be homologous to stromelysin, may play a major
role in matrix degradation. Increased expression in metastatic
cells of another gene, mts-1, has been described recently
(Ebralidze et al., 1989). In this study the phenol-emulsion
reassociation technique (PERT) (Kohne et al., 1977) was
used to enrich for cDNA molecules specific for metastatic
cells. The amino acid sequence deduced from the nucleotide
sequence of the mts-l gene was identical to the mouse Ca2"
binding protein (Ebralidze et al., 1989; Tulchinsky et al.,
1990). Assignment of the mts-l gene to the Ca2" binding
protein family gives little indication of its possible role in
tumour dissemination. However, it has long been postulated
that a defect in calcium binding activity might lead to a loss
in cell-cell adhesiveness that would facilitate cell shedding
from malignant tumours (Coman, 1944). Since some of the
cell-cell adhesion molecules, such as L-CAM and N-cadherin,
are calcium dependent it may be possible that cellular disso-
ciation in malignancy occurs because of perturbations in the
activity of these molecules as a consequence of the mts-1 gene
product acting as a calcium sink.
To underline the fact that the metastatic phenotype may be
a consequence both of increased expression of certain genes
or decreased expression of others, other genes isolated by
differential hybridisation protocols have been downregulated
in expression in metastatic variants. Thus Schalken et al.
(1988) found that fibronectin mRNA was down-modulated in
metastatic variants of a rat prostate tumour. Similarly, using
a rat mammary adenocarcinoma, a family of RNA trans-
cripts encoded by the gene WDNM1 have been detected
which are expressed at a 20-fold higher level in non-meta-
static cell lines (Dear et al., 1988). Application of the subtrac-
tive hybridisation techniques to the same system resulted in
the identification of a second gene, WDNM2, encoding
1.7 kb mRNA, corresponding to a 28-30 kDa protein, which
was regulated transcriptionally in a positive correlation with
the non-metastatic phenotype (Dear et al., 1989). No light
has been shed on the possible role that WDNM2 has in the
malignant process with the recent notification that a full
length cDNA sequence of the WDNM2 gene exhibited com-
plete homology to the rat NAD(P)H:menadione oxidoreduc-
tase cDNA (Dear, 1990).
Currently the most interesting and the most exciting gene
implicated in regulating metastasis which has been identified
by the differential hybridisation procedure is the nm23 gene
identified by Steeg and co-workers (Steeg et al., 1988).
Originally identified and isolated from variant lines of the
K1735 murine melanoma the human homologue of this gene
has now been cloned (Steeg & Liotta, 1990). Expression of
nm23 mRNA has been shown to be down-regulated in meta-
static variants in a wide variety of experimental tumour
models. Much more interesting than the results from even
these well characterised rodent models is the demonstration
of an association between lack of expression and high metas-
tatic potential in human infiltrating ductal breast carcinomas
(Bevilacqua et al., 1989). Antibodies raised against peptides
corresponding to the N-terminus of the predicted protein
product of the nm23 gene have now been used to show that
the situation at the protein level mirrors that occurring at the
mRNA level (Steeg & Liotta, 1990). It seems that nm23 is
perhaps the best candidate for a metastasis suppressor gene
yet identified. Analysis by Southern blot of matched normal
and tumour samples, from patients with lung and renal
carcinomas, for restriction fragment length polymorphism
has revealed loss of heterozygosity in 40-60% of cases,
consistent with a suppressor type function (Steet & Liotta,
1990). Transfection of the nm23 gene, under the control of
various promoters, back into metastatic lines results in loss
of both experimental and spontaneous metastatic activity in
those lines with high level expression of the transfected gene
and seems to confirm the suppressor function of nm23 (Steeg
& Liotta, 1990). This type of experiment would seem to be
an absolute requirement to verify that candidate genes are
indeed metastasis suppressor genes. Care, however, must be
taken in both the performance of such experiments and in
the interpretation of results accruing from them. Assessment
of metastatic capacity solely by the monitoring of experi-
mental metastasis, where tumour cells are injected directly
into the bloodstream and resultant colonies are scored in the
target organ at a later date, may simply identify tumour
suppressor genes rather than specific metastasis suppressor
genes. It is imperative therefore that measurement of the
tumourigenicity of the various transfectants be included in
the assay; either by separate injection or by using the spon-
taneous metastasis assay utilised by Steeg and Liotta (1990).
The demonstration of 78% identity between the predicted
amino acid sequence of the nm23 gene and the Drosophila
abnormal wing disc (awd) gene (Rosengard et al., 1989)
raises intriguing questions about the role of this highly con-
served gene in the processes of cellular differentiation and
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aberrant situation operating in tumour dissemination. As if
to emphasise the conservation of nm23 throughout the
animal kingdom it has recently become apparent that there is
striking homology between nm23 and a nucleoside diphos-
phate (NDP) kinase isolated from Dictyostelium (Wallet et
al., 1990). It may well be that this conservation will facilitate
the understanding of the biochemical basis of nm23 gene
activity.
Summary and conclusions
Gain or loss of a wide variety of different gene products has
been documented during the progression of various cancers
(Klein & Klein, 1985). Many of these alterations have been
detected initially by variation in reactivity to monoclonal
antibodies in tissues isolated from discrete stages of tumour
development. Subsequently the genes coding for the antigens
recognised by these antibodies have been cloned and
sequenced. Thus in malignant melanoma, for example, in-
creased expression of the cell adhesion molecule ICAM-1 has
been associated with an increased risk of metastasis (Johnson
et al., 1989). A similar correlation between enhanced expres-
sion and late stage disease in melanoma has also been report-
ed for the MUC 18 antigen, which shows sequence similarity
to the neural cell adhesion molecules of the immunoglobulin
superfamily (Lehmann et al., 1989). Somewhat in contrast to
these results in malignant melanomas, where increasing
malignancy appears to be correlated with increased expres-
sion of cell-cell adhesion molecules, are the findings from
colorectal cancer where allelic deletions involving chromo-
some 18q, which tend to occur relatively late in progression,
have been determined to involve a gene specifying a protein
with sequence similarity to neural cell adhesion molecules
(Fearon et al., 1990).
Whether these changes in genes encoding cell-cell adhesion
molecules are a necessary step in the development of metas-
tatic capacity or whether they are 'accessory' changes (Klein
& Klein, 1985) remains to be determined. Most probably,
like described changes in such molecules as class I antigens or
integrin receptors, they play an important though not neces-
sarily deterministic role in modulating metastatic behaviour.
The direct approach to identifying genes which are able to
confer the metastatic phenotype has been by utilisation of
transfection assays. Results from such assays have shown
clearly that some, though not all, of the already identified
oncogenes are capable of inducing the requisite changes in
tumourigenic, but benign cells. More surprisingly, given the
view that metastasis is a multistep phenomenon, these same
genes have been found to have the capacity to convert non-
tumourigenic fibroblasts directly to the fully malignant
phenotype. A finding which raises interesting questions about
metastatic capacity arising late in tumour progression. While
the use of high molecular weight genomic DNA has brought
similar malignant conversion no novel gene has, as yet, been
characterised from such studies.
Differential hybridisation of cDNA libraries, which would
not discriminate between accessory or deterministic genes,
has identified a series of both known and novel genes
expressed to different degrees in variants of differing metas-
tatic capacity of which one, nm23, appears to be the most
likely candidate for a metastasis-regulating gene. It is likely
that these types of studies will continue in the future and will
result in the isolation of interesting candidate genes. Analysis
of these genes both in vitro and in transgenic mice (Hanahan,
1988) will offer additional insights into the genetic regulation
of tumour metastasis, with the promise that such insights
may lead to new treatment strategies aimed at protein pro-
ducts specifically involved in tumour dissemination.
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